Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Trial Profile

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Nanjing Sike Pharmaceutical
  • Most Recent Events

    • 26 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 07 Jul 2014 Planned primary completion date changed from 1 Oct 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
    • 02 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top